{
  "abstract": "Bevacizumab is an important component of first-line therapy for advanced epithelial ovarian cancer; however, the precise identification of patients who will benefit and how to optimize its use in the era of poly (ADP-ribose) polymerase inhibitors (PARPi) remains a core challenge in clinical practice. This review systematically revisits the pivotal phase III trials GOG-0218 and ICON7, together with their inherent limitations, with a particular focus on the role of KELIM score as a dynamic marker of chemotherapy sensitivity in predicting bevacizumab efficacy. Based on the interaction test from GOG-0218, the available evidence suggests that BRCA/homologous recombination deficiency (HRD) status does not alter the single-agent activity of bevacizumab; however, these genetic markers remain crucial for guiding PARPi or combination regimens. A key clinical dilemma arises when patients with a BRCA mutation have already received bevacizumab during first-line chemotherapy: should bevacizumab be continued or discontinued during the maintenance phase? This review presents a preference analysis and individualized decision-making factors based on available indirect evidence and current guidelines. Finally, a clinical decision pathway that integrates KELIM assessment with HRD testing is proposed to provide an evidence-based reference framework for the rational use of bevacizumab in first-line advanced ovarian cancer.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "Review",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "name": "Lan Zhong"
    },
    {
      "name": "Liang Song"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3cqj21jvrfxcw.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1931140",
  "fulltext_url": null,
  "id": "3cqj21jvrfxcw",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1931140",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "feed-journal",
      "medicine/pharmacology-toxicology"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-09",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/3cqj21jvrfxcw.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T18:20:19Z",
      "native_id": "10.3389/fphar.2026.1931140",
      "source": "feed-frontiers",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1931140"
    },
    {
      "first_seen": "2026-11-10T00:21:41Z",
      "native_id": "10.3389/fphar.2026.1931140",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1931140/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "feed-journal:medicine/pharmacology-toxicology",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making",
  "title_text": "Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T00:21:41Z",
  "url": "https://research.draconitic.com/paper/3cqj21jvrfxcw",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}